drugset / Trial / NCT00086112

Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.

NCT00086112

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.

Timeline

Start
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 1 mg Oral
Subject Risperidone Other / unclassified 2 mg Oral

Indications